We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Angioplasty Beats Drugs for Treating Heart Attacks

By HospiMedica staff writers
Posted on 07 May 2002
A study has found that heart attack patients fare better when treated with angioplasty rather than with clot-busting drugs. More...
The findings were reported in the April 17, 2002, issue of the Journal of the American Medical Association (JAMA).

The study involved 451 heart attack patients admitted to 11 US hospitals and randomly assigned to receive angioplasty or clot-busting drugs. Also, 70% of the angioplasty patients received a stent. Hospitals lacking cardiac surgery capability, required in many US hospitals that perform angioplasty, were given temporary waivers for the study. The results six months later showed that the combined incidence of death, repeat heart attacks, and stroke was 40% lower for the angioplasty patients (12%) than for those who took clot-busting drugs (20%).

For the study, investigators from Johns Hopkins Medical School (Baltimore, MD, USA), created a program to develop angioplasty at each of the hospitals involved. This involved setting standards, training staff, developing logistics, and creating ways to manage quality and errors.

"Given the superiority of primary angioplasty over thrombolytic therapy, it is important that health-care policy be amended to provide the greatest number of patients access to this better form of therapy,” said Dr. Thomas Aversano, lead author and associate professor of medicine at Hopkins. "It should not be a matter of chance or geography that determines what kind of care a heart attack patient receives.”




Related Links:
Johns Hopkins

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Radiology System
Riviera SPV AT
PACS Workstation
PaxeraView PRO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.